Skip to main content

Table 1 Population characteristics and comorbidities in schizophrenia and NAP patients in Stockholm, Sweden in 2012

From: Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: a cross-sectional study

  Study population
Schizophrenia NAP   
N 7284 11,485   
% males 57 49   
Age (mean, SD) 52.7 (14.4) 49.5 (18.5)   
Age (median) 53 (43–62) 48 (35–62)   
1-year prevalence (%, 2012) RR 95% CI
 Diabetesa 6.9 4.8 1.45 1.28–1.63
 Hypertensiona 7.9 9.7 0.82 0.74–0.90
 Obesity 2.2 2.2 0.97 0.8–1.18
 Substance abusea 7.9 11.7 0.63 0.61–0.74
 Self-harma 0.6 0.9 0.65 0.45–0.93
12-year prevalence (%, 2000–2012)
 Diabetesa 12.5 7.9 1.58 1.44–1.72
 Hypertensiona 17.0 19.3 0.88 0.83–0.94
 Obesitya 9.9 8,0 1.23 1.12–1.35
 Substance abusea 24.8 28.4 0.87 0.83–0.92
 Self-harma 3.5 4.3 0.82 0.70–0.95
  1. Note: If ever (2000–2012) diagnosed with schizophrenia, then considered part of the schizophrenia group only, irrespective of NAP ever diagnosed
  2. astatistically significant difference in RR between the two diagnostic groups (95% CI for RR)